Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes
Valérie Boudreau, Adèle Coriati, Katherine Desjardins, et al.
Journal of Cystic Fibrosis (2016) Vol. 15, Iss. 2, pp. 258-260
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis
Andrea Granados, Christine L. Chan, Katie Larson Ode, et al.
Journal of Cystic Fibrosis (2019) Vol. 18, pp. S3-S9
Open Access | Times Cited: 125
ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis
Michael Wilschanski, À. Munck, Estefania Carrion, et al.
Clinical Nutrition (2023) Vol. 43, Iss. 2, pp. 413-445
Closed Access | Times Cited: 29
ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis‐related diabetes in children and adolescents
Katie Larson Ode, Manfred Ballman, Alberto Battezzati, et al.
Pediatric Diabetes (2022) Vol. 23, Iss. 8, pp. 1212-1228
Open Access | Times Cited: 33
Hemoglobin A1c Accurately Predicts Continuous Glucose Monitoring–Derived Average Glucose in Youth and Young Adults With Cystic Fibrosis
Christine L. Chan, Emma Hope, Jessica Thurston, et al.
Diabetes Care (2018) Vol. 41, Iss. 7, pp. 1406-1413
Open Access | Times Cited: 50
Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis
Kevin J. Scully, Jordan S. Sherwood, Kimberly Martin, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 4, pp. e1444-e1454
Open Access | Times Cited: 28
Screening for Cystic Fibrosis-Related Diabetes: Matching Pathophysiology and Addressing Current Challenges
Valérie Boudreau, Quitterie Reynaud, Catherine Lehoux Dubois, et al.
Canadian Journal of Diabetes (2016) Vol. 40, Iss. 5, pp. 466-470
Closed Access | Times Cited: 38
Cystic Fibrosis-Related Diabetes Screening in Adults: A Gap Analysis and Evaluation of Accuracy of Glycated Hemoglobin Levels
Julie Gilmour, Jenna Sykes, Edward Etchells, et al.
Canadian Journal of Diabetes (2018) Vol. 43, Iss. 1, pp. 13-18
Open Access | Times Cited: 36
Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard?
Catherine Mainguy, G. Bellon, V. Delaup, et al.
Journal of Pediatric Endocrinology and Metabolism (2016) Vol. 30, Iss. 1
Closed Access | Times Cited: 33
Cystic fibrosis-related diabetes: an update on pathophysiology, diagnosis, and treatment
Crésio Alves, Thais DellaManna, Cristiano Túlio Maciel Albuquerque
Journal of Pediatric Endocrinology and Metabolism (2020) Vol. 33, Iss. 7, pp. 835-843
Closed Access | Times Cited: 30
Cystic fibrosis-related diabetes: Prevalence, screening, and diagnosis
Swapnil Khare, Marisa Desimone, Nader Kasim, et al.
Journal of Clinical & Translational Endocrinology (2021) Vol. 27, pp. 100290-100290
Open Access | Times Cited: 27
20 years of the Montreal Cystic Fibrosis Related Diabetes Screening Cohort: key insights
Laure Alexandre‐Heymann, Valérie Boudreau, Dean Lim, et al.
European Respiratory Review (2025) Vol. 34, Iss. 176, pp. 240220-240220
Open Access
Advances in cystic fibrosis-related diabetes: Current status and future directions
F. Lurquin, Martin Buysschaert, Vanessa Preumont
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 11, pp. 102899-102899
Open Access | Times Cited: 8
Screening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis
Laurence Weiss, Philippe Reix, Helen Mosnier-Pudar, et al.
Diabetes & Metabolism (2023) Vol. 49, Iss. 3, pp. 101444-101444
Open Access | Times Cited: 8
Screening for cystic fibrosis‐related diabetes and prediabetes: Evaluating 1,5‐anhydroglucitol, fructosamine, glycated albumin, and hemoglobin A1c
Kalie L. Tommerdahl, John T. Brinton, Tim Vigers, et al.
Pediatric Diabetes (2019) Vol. 20, Iss. 8, pp. 1080-1086
Open Access | Times Cited: 18
Glycated Hemoglobin as a First-line Screening Test for Cystic Fibrosis‒Related Diabetes and Impaired Glucose Tolerance in Children With Cystic Fibrosis: A Validation Study
Florence Racine, Azadeh Shohoudi, Valérie Boudreau, et al.
Canadian Journal of Diabetes (2021) Vol. 45, Iss. 8, pp. 768-774
Closed Access | Times Cited: 13
Evolving Mechanistic Views and Emerging Therapeutic Strategies for Cystic Fibrosis–Related Diabetes
John C. Yoon
Journal of the Endocrine Society (2017) Vol. 1, Iss. 11, pp. 1386-1400
Open Access | Times Cited: 16
Validation of a Stepwise Approach Using Glycated Hemoglobin Levels to Reduce the Number of Required Oral Glucose Tolerance Tests to Screen for Cystic Fibrosis–Related Diabetes in Adults
Valérie Boudreau, Quitterie Reynaud, Anne Bonhoure, et al.
Canadian Journal of Diabetes (2018) Vol. 43, Iss. 3, pp. 161-162
Closed Access | Times Cited: 14
A provider survey of cystic fibrosis related diabetes screening and management practices at North American CF centers
Rebecca Hicks, Katie Larson Ode, Tim Vigers, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 4
A glycosylated hemoglobin A1c above 6% (42 mmol/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis
Kathryn J. Potter, Florence Racine, Anne Bonhoure, et al.
Diabetes & Metabolism (2023) Vol. 49, Iss. 4, pp. 101455-101455
Closed Access | Times Cited: 4
The use of fructosamine in cystic fibrosis-related diabetes (CFRD) screening
Grace Y. Lam, Michelle Doll-Shankaruk, Jan Dayton, et al.
Journal of Cystic Fibrosis (2017) Vol. 17, Iss. 1, pp. 121-124
Open Access | Times Cited: 12
Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF
Kevin J. Scully, Laura Brenner, Kimberly Martin, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 1
Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: A single centre experience
Anjali Santhakumar, Francine Lewis, Joanna Pickles, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 5, pp. 853-856
Closed Access | Times Cited: 1
Sensitivity and specificity of cystic fibrosis-related diabetes screening methods: which test should be the reference method?
Valérie Boudreau, Catherine Lehoux Dubois, Katherine Desjardins, et al.
Journal of Pediatric Endocrinology and Metabolism (2017) Vol. 30, Iss. 8
Open Access | Times Cited: 9
How reliable is your HbA1c test? Revisiting the use of HbA1c in cystic fibrosis-related diabetes (CFRD) screening
Grace Y. Lam, Shelby Sissons, Maeve P. Smith, et al.
Journal of Cystic Fibrosis (2019) Vol. 18, Iss. 2, pp. e14-e15
Open Access | Times Cited: 9
Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis
Johann Colomba, Silvia R. Netedu, C. Lehoux-Dubois, et al.
PLoS ONE (2019) Vol. 14, Iss. 7, pp. e0219855-e0219855
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top